Maurizio Cavallini1, Marco Papagni1, Timothy J Ryder2, Mariagrazia Patalano3. 1. Unit of Dermatology and Dermatosurgery, CDI Hospital, Milan, Italy. 2. Biological Communications Limited, London, United Kingdom. 3. Studio Medico Dott.ssa MgPatalano, Messina, Italy.
Abstract
BACKGROUND: VYC-12 is a novel hyaluronic acid-based dermal filler designed to treat fine lines and improve skin quality. A specialist digital camera and proprietary Digital Analysis of the Cutaneous Surface (DACS) software have previously been used to objectively measure changes in skin features. OBJECTIVE: To assess the effect of facial treatment with VYC-12 on skin texture using the specialist camera. MATERIALS AND METHODS: This was a prospective, open-label, 2-center study of 40 women aged 35 to 60 years treated with multiple, microdepot intradermal injections of VYC-12 (2 mL in the face; 1 mL in the neck if required). Eight patients (20.0%) required a touch-up at Day 45. Images were acquired using the specialist camera at baseline and 45 days and 6 months after treatment, and were analyzed by DACS. Clinical improvements were also assessed subjectively using the Global Aesthetic Improvement Scale (GAIS). RESULTS: VYC-12 improved skin texture from baseline after 45 days (mean improvement: 25.9% ± 9.2%) and 6 months (mean improvement: 30.7% ± 18.2%). Improvements were also evident using the GAIS. There were no major adverse events. CONCLUSIONS: VYC-12 improves skin quality, as measured using an objective, fast, and reproducible measuring tool. VYC-12 represents a valuable addition to the treatment armamentarium.
BACKGROUND:VYC-12 is a novel hyaluronic acid-based dermal filler designed to treat fine lines and improve skin quality. A specialist digital camera and proprietary Digital Analysis of the Cutaneous Surface (DACS) software have previously been used to objectively measure changes in skin features. OBJECTIVE: To assess the effect of facial treatment with VYC-12 on skin texture using the specialist camera. MATERIALS AND METHODS: This was a prospective, open-label, 2-center study of 40 women aged 35 to 60 years treated with multiple, microdepot intradermal injections of VYC-12 (2 mL in the face; 1 mL in the neck if required). Eight patients (20.0%) required a touch-up at Day 45. Images were acquired using the specialist camera at baseline and 45 days and 6 months after treatment, and were analyzed by DACS. Clinical improvements were also assessed subjectively using the Global Aesthetic Improvement Scale (GAIS). RESULTS:VYC-12 improved skin texture from baseline after 45 days (mean improvement: 25.9% ± 9.2%) and 6 months (mean improvement: 30.7% ± 18.2%). Improvements were also evident using the GAIS. There were no major adverse events. CONCLUSIONS:VYC-12 improves skin quality, as measured using an objective, fast, and reproducible measuring tool. VYC-12 represents a valuable addition to the treatment armamentarium.
Authors: Dario Bertossi; Riccardo Nocini; Berend van der Lei; Philippe Magistretti; Alessandro Gualdi; Ali Pirayesh; Alberto Marchetti Journal: Plast Reconstr Surg Glob Open Date: 2021-11-24